Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liminatus PharmaLIMN -4.41%13 PB Ratio is 12.90 as of Sep. 13, 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,226 Biotechnology companies, Liminatus Pharma ranks worse than 89.89% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-13), Liminatus Pharma's share price is $3.47. Liminatus Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was $0.27. Hence, Liminatus Pharma's PB Ratio of today is 12.90.
The historical rank and industry rank for Liminatus Pharma's PB Ratio or its related term are showing as below:
LIMN'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 12.9
Current: 12.9
During the past 4 years, Liminatus Pharma's highest PB Ratio was 12.90. The lowest was 0.00. And the median was 0.00.
LIMN's PB Ratio is ranked worse than 89.89% of 1226
companies
in the Biotechnology industry
Industry Median: 2.9
vs LIMN: 12.90
During the past 3 years, the average Book Value Per Share Growth Rate was 4.40% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Liminatus Pharma was 4.40% per year. The lowest was 4.40% per year. And the median was 4.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Liminatus Pharma PB Ratio Related Terms
Liminatus Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Liminatus Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Liminatus Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liminatus Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liminatus Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Liminatus Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Liminatus Pharma (LIMN) has a PB Ratio of 12.90 as of Sep. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Liminatus Pharma and its competitors. According to the industry distribution chart, Liminatus Pharma ranks #1102 out of 1226 companies in the Biotechnology industry, placing it in the top 89.9%.
Is Liminatus Pharma's PB Ratio too high?
Liminatus Pharma's current PB Ratio is 12.90. The Biotechnology industry median PB Ratio is 2.90. Liminatus Pharma's value of 12.90 is 344.8% above this industry median. Based on the distribution chart, Liminatus Pharma ranks #1102 out of 1226 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's PB Ratio compare to NIKI and KAPA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #1102 out of 1226 companies for PB Ratio. This places Liminatus Pharma in the lower half of its industry. The industry median PB Ratio is 2.90. Liminatus Pharma's value of 12.90 is 344.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liminatus Pharma's current PB Ratio of 12.90 is 344.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Liminatus Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current PB Ratio is 12.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current PB Ratio of 12.90. The current PB Ratio is 12.90 and 344.8% above the Biotechnology industry median of 2.90. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current PB Ratio is 12.90 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score
Get the complete analysis for LIMN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIMN has been successfully added to your 
